Novo Nordisk - ADR
NYSE:NVO 4:00:00 PM EDT
| Market Cap (Intraday) | 232.32B |
| Current PE | 2.22 |
| Forward PE | 17.17 |
| 2yr Forward PE | 14.65 |
| 10-Day MA | $70.70 |
| 50-Day MA | $68.83 |
| 200-Day MA | $89.14 |
Novo Nordisk - ADR Stock, NYSE:NVO
Novo All�©, Novo All�© 1, Bagsv��rd, Capital Region 2880
Denmark
Phone: +45.44.44.88.88
Number of Employees: 76302
Description
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in BagsvÃ?Â?rd, Denmark.